MarketPulse

Stargardt disease

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Belite Bio Advances Stargardt Disease Drug Toward FDA Approval, Reports $798.6M Cash

Belite Bio initiates rolling FDA submission for tinlarebant to treat Stargardt disease, with Q2 2026 completion expected. Company reported $798.6M in cash and Q1 net loss of $26.9M.
BLTEFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Belite Bio's Tinlarebant Wins Swiss Orphan Drug Status Ahead of FDA Filing

Belite Bio secures Swiss orphan drug status for tinlarebant, advancing rare eye disease treatment toward FDA approval expected Q2 2026.
BLTEFDA approvalStargardt disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Belite Bio to Detail Q1 2026 Results, Tinlarebant Trial Progress on May 20

Belite Bio will host webcast May 20, 2026 to discuss Q1 financial results and provide updates on tinlarebant trials for retinal diseases.
BLTEPhase 3 trialwebcast
GlobeNewswire Inc.GlobeNewswire Inc.··Belite Bio, Inc

Belite Bio Pursues FDA Approval for Tinlarebant, Potential First Stargardt Disease Treatment

Belite Bio begins rolling NDA submission to FDA for tinlarebant, a potential breakthrough oral therapy for rare Stargardt disease, targeting 2027 commercialization.
BLTEFDA approvalrare disease
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

AAVantgarde Bolsters Leadership with Adverum Veteran Philip Lao as SVP

AAVantgarde Bio names Philip Lao as SVP of Business Development. Lao previously led Adverum's sale to Eli Lilly, bringing pharma expertise from Novartis, Pfizer, and Takeda.
LLYstrategic partnershipsgene therapy